← Leaderboards
Hojong Yoon
Harvard University
$744,678
Attributed
$744,678
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $249K · FY2020–25$250K$187.5K$125K$62.5K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$744,678 · 4
By mechanism
K00$291,515 · 1
R00$249,000 · 1
K99$171,180 · 1
F99$32,983 · 1
Top collaborators
No co-investigators on record.
Most similar at Harvard University
Same institution · by research overlap
- Christina Woo$7,027,736
- Brian Liau$6,240,615
Others in their field
Other Emerging Leaders on “Targeted Cancer Therapy”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$70,594,703
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$56,581,612
- Crystal Mackall · Children'S Hosp Of Philadelphia$16,367,876
- Tareq Al Baghdadi · Saint Joseph Mercy Health System$16,009,505
- Jeremy James Martinson · University Of Pittsburgh At Pittsburgh$14,031,836
Research focus
Targeted Cancer TherapySuccessPolymersPolymerizationProteomeSmall MoleculeInnovationLibrariesModalityPharmacologyProtein Protein InteractionProteinsRecruitCancer BiologyComplexGluesBcl6 GeneInsightAntineoplastic AgentsMalignant NeoplasmsMolecularOncogenicProtein DegradationTranscription Factor
Grant awards (6)
A Chemoproteomic Approach to Identify Molecular Glues for Targeted Cancer Therapy$249,000
R00 · FY2025 · CA · contact PI
A Chemoproteomic Approach to Identify Molecular Glues for Targeted Cancer Therapy$171,180
K99 · FY2024 · CA · contact PI
Expanding pharmacological modalities for targeted cancer therapy$101,247
K00 · FY2023 · CA · contact PI
Expanding pharmacological modalities for targeted cancer therapy$96,632
K00 · FY2022 · CA · contact PI
Expanding pharmacological modalities for targeted cancer therapy$93,636
K00 · FY2021 · CA · contact PI
Expanding pharmacological modalities for targeted cancer therapy$32,983
F99 · FY2020 · CA · contact PI